NO20026252L - Aza-broforbundet-bicykliske aminosyrederivater som <alfa>4 integrin antagonister - Google Patents
Aza-broforbundet-bicykliske aminosyrederivater som <alfa>4 integrin antagonisterInfo
- Publication number
- NO20026252L NO20026252L NO20026252A NO20026252A NO20026252L NO 20026252 L NO20026252 L NO 20026252L NO 20026252 A NO20026252 A NO 20026252A NO 20026252 A NO20026252 A NO 20026252A NO 20026252 L NO20026252 L NO 20026252L
- Authority
- NO
- Norway
- Prior art keywords
- alfa
- amino acid
- acid derivatives
- bridged bicyclic
- integrin antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21569500P | 2000-06-30 | 2000-06-30 | |
US09/891,602 US6960597B2 (en) | 2000-06-30 | 2001-06-26 | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
PCT/US2001/020857 WO2002002556A2 (en) | 2000-06-30 | 2001-06-29 | AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS α4 INTEGRIN ANTAGONISTS |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20026252D0 NO20026252D0 (no) | 2002-12-27 |
NO20026252L true NO20026252L (no) | 2003-02-26 |
Family
ID=26910288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20026252A NO20026252L (no) | 2000-06-30 | 2002-12-27 | Aza-broforbundet-bicykliske aminosyrederivater som <alfa>4 integrin antagonister |
Country Status (19)
Country | Link |
---|---|
US (1) | US6960597B2 (pt) |
EP (1) | EP1303492A2 (pt) |
JP (1) | JP2004506612A (pt) |
KR (1) | KR20030014287A (pt) |
CN (1) | CN1449385A (pt) |
AR (1) | AR031853A1 (pt) |
AU (1) | AU2001273095A1 (pt) |
BR (1) | BR0112359A (pt) |
CA (1) | CA2415088A1 (pt) |
HK (1) | HK1052343A1 (pt) |
HU (1) | HUP0301195A2 (pt) |
IL (1) | IL154053A0 (pt) |
MX (1) | MXPA03000814A (pt) |
NO (1) | NO20026252L (pt) |
NZ (1) | NZ523852A (pt) |
PL (1) | PL359997A1 (pt) |
RU (1) | RU2003102631A (pt) |
WO (1) | WO2002002556A2 (pt) |
YU (1) | YU98902A (pt) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6960597B2 (en) | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
AU7874001A (en) | 2000-08-18 | 2002-03-04 | Ajinomoto Kk | Novel phenylalanine derivatives |
DE60124573T2 (de) | 2000-09-29 | 2007-06-21 | Ajinomoto Co., Inc. | Neue phenylalanin-derivate |
US7115628B2 (en) * | 2001-07-18 | 2006-10-03 | Merck & Co., Inc. | Bridged piperidine derivatives as melanocortin receptor agonists |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
CA2514125A1 (en) * | 2003-01-24 | 2004-08-12 | Elan Pharmaceuticals, Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
US20050176755A1 (en) * | 2003-10-31 | 2005-08-11 | Dyatkin Alexey B. | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists |
EP2615087A3 (en) | 2003-12-22 | 2013-08-07 | Ajinomoto Co., Inc. | Phenylalanine derivatives |
WO2005077915A1 (en) * | 2004-02-10 | 2005-08-25 | Janssen Pharmaceutica, N.V. | Pyridazinones as antagonists of a4 integrins |
BRPI0506676A (pt) * | 2004-02-10 | 2007-05-15 | Janssen Phamaceutica N V | piridazinona uréias como antagonistas de integrinas alfa4 |
US7220742B2 (en) * | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
KR20070029733A (ko) | 2004-06-04 | 2007-03-14 | 제넨테크, 인크. | 다발성 경화증의 치료 방법 |
WO2006096807A1 (en) * | 2005-03-08 | 2006-09-14 | Janssen Pharmaceutica N.V. | Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists |
ES2646326T3 (es) | 2005-08-03 | 2017-12-13 | Sprout Pharmaceuticals, Inc. | Uso de flibanserina en el tratamiento de la obesidad |
CA2619402C (en) * | 2005-08-15 | 2015-02-03 | Boehringer Ingelheim International Gmbh | Method for producing betamimetics |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
DE602007004615D1 (de) | 2006-06-30 | 2010-03-18 | Boehringer Ingelheim Pharma | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen |
UY30543A1 (es) * | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de beta- agonistas |
UY30542A1 (es) * | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de agonistas beta |
CL2008002693A1 (es) | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad |
AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
CA2686480A1 (en) | 2008-12-15 | 2010-06-15 | Boehringer Ingelheim International Gmbh | New salts |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
CA2781390A1 (en) * | 2009-12-14 | 2011-06-23 | Inspire Pharmaceuticals, Inc. | Bridged bicyclic rho kinase inhibitor compounds, composition and use |
WO2011094890A1 (en) * | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
US8999975B2 (en) * | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
AU2013215332A1 (en) | 2012-01-31 | 2014-09-04 | Genentech, Inc. | Anti-Ig-E M1' antibodies and methods using same |
US8877775B2 (en) | 2013-03-14 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C |
ES2845473T3 (es) | 2013-03-14 | 2021-07-26 | Boehringer Ingelheim Int | (Bencil-ciano-metil)-amidas sustituidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico inhibidores de la catepsina- C |
ES2864349T3 (es) * | 2013-06-11 | 2021-10-13 | Receptos Llc | Nuevos moduladores del receptor GLP-1 |
JP6529575B2 (ja) | 2014-08-01 | 2019-06-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換オキセタンおよびそれらのカテプシンcの阻害薬としての使用 |
WO2016038007A1 (en) | 2014-09-12 | 2016-03-17 | Boehringer Ingelheim International Gmbh | Spirocyclic inhibitors of cathepsin c |
KR20180075537A (ko) | 2015-10-06 | 2018-07-04 | 제넨테크, 인크. | 다발성 경화증을 치료하기 위한 방법 |
EP3939989A1 (en) | 2016-11-11 | 2022-01-19 | Zealand Pharma A/S | Cyclic peptides multimers targeting alpha 4beta 7 integrin |
CN112969504B (zh) * | 2018-10-30 | 2024-04-09 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
AU2019373240B2 (en) | 2018-10-30 | 2023-04-20 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
KR102641718B1 (ko) | 2018-10-30 | 2024-02-29 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체 |
WO2021030438A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3905971A (en) * | 1971-03-29 | 1975-09-16 | Pfizer | 2-Phenyl-as-triazine-3,5(2H,4H)diones |
JPS6314774A (ja) | 1986-07-07 | 1988-01-21 | Mitsubishi Chem Ind Ltd | ピリダジノン誘導体又はその塩類 |
IE62890B1 (en) * | 1988-12-06 | 1995-03-08 | Hafslund Nycomed Pharma | New piperazinylalkyl-3(2h)-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure |
US6090785A (en) * | 1992-10-15 | 2000-07-18 | Merck & Co., Inc. | Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents |
US5525623A (en) * | 1993-03-12 | 1996-06-11 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
US5523308A (en) * | 1995-06-07 | 1996-06-04 | Costanzo; Michael J. | Peptidyl heterocycles useful in the treatment of thrombin related disorders |
US5827860A (en) * | 1995-06-07 | 1998-10-27 | Ortho Pharmaceutical Corporation | Peptidyl heterocycles useful in the treatment of thrombin related disorders |
US5827866A (en) * | 1995-06-07 | 1998-10-27 | Ortho Pharmaceutical Corporation | Peptidyl heterocycles useful in the treatment of thrombin related disorders |
JP2002512625A (ja) | 1997-05-29 | 2002-04-23 | メルク エンド カンパニー インコーポレーテッド | 細胞接着阻害薬としての複素環アミド化合物 |
US6221888B1 (en) * | 1997-05-29 | 2001-04-24 | Merck & Co., Inc. | Sulfonamides as cell adhesion inhibitors |
DE69833654T2 (de) | 1997-05-29 | 2006-12-14 | Merck & Co., Inc. (A New Jersey Corp.) | Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren |
US6291511B1 (en) * | 1997-05-29 | 2001-09-18 | Merck & Co., Inc. | Biarylalkanoic acids as cell adhesion inhibitors |
KR20010022413A (ko) | 1997-07-31 | 2001-03-15 | 진 엠. 듀발 | Vla-4에 의해 매개되는 백혈구 부착을 억제하는 벤질화합물 |
CA2291475A1 (en) | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 |
EP1001973A1 (en) | 1997-07-31 | 2000-05-24 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
US6229011B1 (en) * | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
DK1005445T3 (da) | 1997-08-22 | 2004-10-04 | Hoffmann La Roche | N-alkanoylphenylaninderivater |
PT1005446E (pt) | 1997-08-22 | 2004-06-30 | Hoffmann La Roche | Derivados de n-aroilfenilalanina |
US6455550B1 (en) * | 1997-08-22 | 2002-09-24 | Hoffmann-La Roche Inc. | N-alkanoylphenylalanine derivatives |
EP1027328B1 (en) * | 1997-10-31 | 2006-08-23 | Aventis Pharma Limited | Substituted anilides |
US6191171B1 (en) * | 1997-11-20 | 2001-02-20 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
US6197794B1 (en) | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
DE69919334T2 (de) | 1998-02-26 | 2005-08-04 | Celltech Therapeutics Ltd., Slough | Phenylalaninderivate als inhibitoren von alpha4 integrinen |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
US6121280A (en) | 1998-03-24 | 2000-09-19 | Pfizer Inc. | Azabicyclic rotomase inhibitors |
GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
GB9812088D0 (en) | 1998-06-05 | 1998-08-05 | Celltech Therapeutics Ltd | Chemical compounds |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9821406D0 (en) | 1998-10-01 | 1998-11-25 | Celltech Therapeutics Ltd | Chemical compounds |
ATE299490T1 (de) | 1999-01-22 | 2005-07-15 | Elan Pharm Inc | Multizyklische verbindungen zur hemmung der durch vla-4 vermittelten leukozytenadhäsion |
US6436904B1 (en) * | 1999-01-25 | 2002-08-20 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6407066B1 (en) * | 1999-01-26 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
SK10742001A3 (sk) * | 1999-01-27 | 2002-08-06 | Ortho-Mcneil Pharmaceutical, Inc. | Peptidylové heterocyklické ketóny použiteľné ako inhibítory tryptázy |
PT1154993E (pt) * | 1999-02-18 | 2005-01-31 | Hoffmann La Roche | Derivados de tioamida |
EP1161416B1 (en) * | 1999-03-01 | 2004-04-14 | Elan Pharmaceuticals, Inc. | Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 - receptor antagonists |
AU6903200A (en) * | 1999-08-16 | 2001-03-13 | Merck & Co., Inc. | Heterocycle amides as cell adhesion inhibitors |
AU6909300A (en) * | 1999-08-20 | 2001-03-19 | Merck & Co., Inc. | Substituted ureas as cell adhesion inhibitors |
US20030130166A1 (en) * | 1999-08-24 | 2003-07-10 | Sonia Cunningham | Polynucleotide encoding a human junctional adhesion protein (JAM2) |
IL148544A0 (en) | 1999-09-24 | 2002-09-12 | Genentech Inc | Tyrosine derivatives |
US6534513B1 (en) * | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
DE19950862C5 (de) | 1999-10-21 | 2004-02-26 | Lucas Varity Gmbh | Betätigungseinheit für eine elektronisch gesteuerte Fahrzeugbremsanlage |
WO2001032610A1 (fr) | 1999-10-29 | 2001-05-10 | Kaken Pharmaceutical Co., Ltd. | Derive d'uree, son procede de production, et produit pharmaceutique contenant ce derive d'uree |
JP4788939B2 (ja) | 1999-11-18 | 2011-10-05 | 味の素株式会社 | 新規フェニルアラニン誘導体 |
ATE357433T1 (de) | 1999-12-06 | 2007-04-15 | Hoffmann La Roche | 4-pyrimidinyl-n-acyl-l-phenylanine |
US6380387B1 (en) * | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
NZ518888A (en) | 1999-12-06 | 2004-02-27 | F | 4-pyridinyl-N-acyl-L-phenylalanines |
US6388084B1 (en) * | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
US6849639B2 (en) * | 1999-12-14 | 2005-02-01 | Amgen Inc. | Integrin inhibitors and their methods of use |
CA2394431C (en) * | 1999-12-16 | 2015-06-30 | Jane Relton | Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
JP2003519697A (ja) * | 1999-12-28 | 2003-06-24 | ファイザー・プロダクツ・インク | 炎症性疾患、自己免疫疾患および呼吸器疾患の処置に有用な非ペプチド系のvla−4依存性細胞結合阻害薬 |
EP1253923A1 (en) | 2000-01-28 | 2002-11-06 | Biogen, Inc. | Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses |
US6579889B2 (en) * | 2000-06-22 | 2003-06-17 | Merck & Co., Inc. | Substituted isonipecotyl derivatives as inhibitors of cell adhesion |
US6403584B1 (en) * | 2000-06-22 | 2002-06-11 | Merck & Co., Inc. | Substituted nipecotyl derivatives as inhibitors of cell adhesion |
US6960597B2 (en) | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
WO2002008202A2 (en) | 2000-07-21 | 2002-01-31 | Elan Pharmaceuticals, Inc. | Alpha amino acid derivatives--inhibitors of leukocyte adhesion mediated by vla-4 |
US7015216B2 (en) * | 2000-07-21 | 2006-03-21 | Elan Pharmaceuticals, Inc. | Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors |
AU7874001A (en) | 2000-08-18 | 2002-03-04 | Ajinomoto Kk | Novel phenylalanine derivatives |
US6709192B2 (en) | 2000-09-05 | 2004-03-23 | The Fort Miller Group, Inc. | Method of forming, installing and a system for attaching a pre-fabricated pavement slab to a subbase and the pre-fabricated pavement slab so formed |
CA2422135A1 (en) | 2000-09-14 | 2003-03-13 | Toray Industries, Inc. | Urea derivatives and adhesion molecule inhibitors containing the same as effective ingredients |
GB0028844D0 (en) * | 2000-11-27 | 2001-01-10 | Celltech Chiroscience Ltd | Chemical compounds |
ES2200617B1 (es) | 2001-01-19 | 2005-05-01 | Almirall Prodesfarma, S.A. | Derivados de urea como antagonistas de integrinas alfa 4. |
US6559174B2 (en) * | 2001-03-20 | 2003-05-06 | Merck & Co., Inc. | N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors |
JP4164871B2 (ja) | 2001-07-26 | 2008-10-15 | 味の素株式会社 | 新規フェニルプロピオン酸誘導体 |
-
2001
- 2001-06-26 US US09/891,602 patent/US6960597B2/en not_active Expired - Fee Related
- 2001-06-29 CN CN01814699A patent/CN1449385A/zh active Pending
- 2001-06-29 JP JP2002507808A patent/JP2004506612A/ja active Pending
- 2001-06-29 WO PCT/US2001/020857 patent/WO2002002556A2/en active IP Right Grant
- 2001-06-29 BR BR0112359-9A patent/BR0112359A/pt not_active IP Right Cessation
- 2001-06-29 IL IL15405301A patent/IL154053A0/xx unknown
- 2001-06-29 PL PL01359997A patent/PL359997A1/xx not_active Application Discontinuation
- 2001-06-29 EP EP01952331A patent/EP1303492A2/en not_active Withdrawn
- 2001-06-29 YU YU98902A patent/YU98902A/sh unknown
- 2001-06-29 AU AU2001273095A patent/AU2001273095A1/en not_active Abandoned
- 2001-06-29 KR KR1020027017914A patent/KR20030014287A/ko not_active Application Discontinuation
- 2001-06-29 NZ NZ523852A patent/NZ523852A/en unknown
- 2001-06-29 CA CA002415088A patent/CA2415088A1/en not_active Abandoned
- 2001-06-29 RU RU2003102631/04A patent/RU2003102631A/ru not_active Application Discontinuation
- 2001-06-29 AR ARP010103131A patent/AR031853A1/es unknown
- 2001-06-29 MX MXPA03000814A patent/MXPA03000814A/es unknown
- 2001-06-29 HU HU0301195A patent/HUP0301195A2/hu unknown
-
2002
- 2002-12-27 NO NO20026252A patent/NO20026252L/no not_active Application Discontinuation
-
2003
- 2003-06-19 HK HK03104413.8A patent/HK1052343A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
NO20026252D0 (no) | 2002-12-27 |
WO2002002556A2 (en) | 2002-01-10 |
NZ523852A (en) | 2004-11-26 |
MXPA03000814A (es) | 2004-11-01 |
US20020091115A1 (en) | 2002-07-11 |
IL154053A0 (en) | 2003-07-31 |
HUP0301195A2 (hu) | 2003-08-28 |
EP1303492A2 (en) | 2003-04-23 |
CA2415088A1 (en) | 2002-01-10 |
YU98902A (sh) | 2006-05-25 |
HK1052343A1 (zh) | 2004-02-06 |
AR031853A1 (es) | 2003-10-08 |
KR20030014287A (ko) | 2003-02-15 |
JP2004506612A (ja) | 2004-03-04 |
RU2003102631A (ru) | 2004-09-27 |
AU2001273095A1 (en) | 2002-01-14 |
CN1449385A (zh) | 2003-10-15 |
WO2002002556A3 (en) | 2002-07-18 |
PL359997A1 (en) | 2004-09-06 |
US6960597B2 (en) | 2005-11-01 |
BR0112359A (pt) | 2003-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20026252L (no) | Aza-broforbundet-bicykliske aminosyrederivater som <alfa>4 integrin antagonister | |
DK1163239T3 (da) | Modificerede aminosyreamider som CGRP-antagonister | |
NO20015366D0 (no) | Piperazinderivater som er anvendbare som CCR5-antagonister | |
NO20021780D0 (no) | Bicykliske aminosyrer som farmasöytiske midler | |
HK1058361A1 (en) | Urea derivatives as integrin alpha 4 antagonists | |
NO20021450D0 (no) | Cykliske aminforbindelser som CCR5 antagonister | |
NO20013671D0 (no) | Substituerte bicycliske derivater nyttige som anticancer midler | |
NO20021459L (no) | Piperazin-derivater som 5-HT1B-antagonister | |
NO20043022L (no) | 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister | |
NO20022887D0 (no) | Lipopeptider som antibakterielle midler | |
AU3157801A (en) | Beta-amino acid compounds as integrin antagonists | |
DK1218380T3 (da) | Bicykliske imidazo-3-yl-aminoderivater substitueret i seksledsringen | |
NO20021251D0 (no) | Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister | |
NO20014048D0 (no) | Heterocykliske benzensulfonamid-forbindelser som bradykinin- antagonister | |
DK1181288T3 (da) | Bicycliske oxazolidinoner som antibakterielle midler | |
PL348946A1 (en) | Novel derivatives of n-triazolylmethylpiperazine as antagonists of the neurokinin acceptor | |
ATE309994T1 (de) | Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten | |
AU2002220598A1 (en) | Beta-amino acid derivatives as integrin receptor antagonists | |
NO20011270D0 (no) | Tricykliske <delta>3-piperidiner som <alfa>2-antagonister | |
NO20015237L (no) | Integrinreseptor-antagonister | |
NO996244D0 (no) | Pyrrolidinkarboksylsyrederivater som endotelinantagonister | |
NO20011309D0 (no) | Benzotieno [3,2-c]pyridiner som<alfa>2-antagonister | |
NO20021249L (no) | Tienoisoksazolfenoksyusubstituerte etyl- og propylderivater anvendbare som D4antagonister | |
SI1383750T1 (sl) | Derivati uree kot integrin alfa 4 antagonisti | |
SI1155013T1 (en) | Heterocyclic benzenesulphonamide compounds as bradykinine antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |